PATENTS- U.S. patent:Antibodies specific for human prostate glandular kallikrein.(Patent No.M & G 1016.62-US-01) (1996).Inventors:Drs. D.J. Tindall, C.Y.F. Young and G. G. Klee.
- Republic of Sorth Africa patent: N0. 95/3727 Recombinant hK2 polypeptide. 1996.
- US patent: DNA encoding hK2 variant polypeptides (Patent No. 6013471) (01/11/2000). Drs. D.J. Tindall, C.Y.F. Young and G.G. Klee et al.
- US patent (Patent Number 6,093,796; issured on July 25,2000): Recombinant hK2 polypeptide. Drs. D.J. Tindall, C.Y.F. Young and G.G. Klee et al.
- A License to Hybritech, Inc.: Immunoassays for human glandular kallikrein-1 (hK2) (1993-present)
- US patent (Patent Number 6,235,486; issured on May 22,2001):Method for Detection for Breast Cancer.
- Australia patent No. 737659, Method for Detection for metastatic prostate Cancer. 2001.
- US patent (Patent Number 6,479,263 B1; issured on Nov. 12, 2002):Method for Detection for Micrometastatic Prostate Cancer.
- USA patent No. US6,656,969 B2. Methods and compositions for inhibiting the proliferation of prostate cancer cells. Dec.2, 2003.
- USA patent No. US6,680,342 B2. Methods and compositions for inhibiting the proliferation of prostate cancer cells. Jan. 20, 2004.
- 2004 Patent provision:EV284452731US (60/487/553): Methods and compositions for diagnosis, staging and prognosis of prostate cancer.
- European patent No. 0974057 approved on Sept. 21 2005 for "Method to detect HK2 polypeptides"
|
